keyword
MENU ▼
Read by QxMD icon Read
search

Hiv statin

keyword
https://www.readbyqxmd.com/read/29770749/rosuvastatin-and-atorvastatin-preserve-renal-function-in-hiv-1-infected-patients-with-chronic-kidney-disease-and-hyperlipidaemia
#1
Leonardo Calza, Vincenzo Colangeli, Marco Borderi, Roberto Manfredi, Lorenzo Marconi, Isabella Bon, Maria Carla Re, Pierluigi Viale
BACKGROUND: Hyperlipidaemia is a risk factor for the progression of chronic kidney disease (CKD), which is a frequent comorbidity in patients with HIV-1 infection, but the renal effects of statins remain unclear. METHODS: We performed an observational, prospective study of HIV-infected patients on suppressive antiretroviral therapy, with CKD and hyperlipidaemia, and starting a lipid-lowering treatment with rosuvastatin, atorvastatin or omega-3 fatty acids. CKD was defined as an estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1...
June 2018: HIV Clinical Trials
https://www.readbyqxmd.com/read/29762344/use-of-nonantiretroviral-medications-that-may-impact-neurocognition-patterns-and-predictors-in-a-large-long-term-hiv-cohort-study
#2
Kendra K Radtke, Peter Bacchetti, Kathryn Anastos, Daniel Merenstein, Howard Crystal, Roksana Karim, Kathleen M Weber, Andrew Edmonds, Anandi N Sheth, Margaret A Fischl, David Vance, Ruth M Greenblatt, Leah H Rubin
BACKGROUND: Neurocognitive impairment is a frequent and often disabling comorbidity of HIV infection. In addition to antiretroviral therapies, individuals with HIV infection may commonly use nonantiretroviral medications that are known to cause neurocognitive adverse effects (NC-AE). The contribution of NC-AE to neurocognitive impairment is rarely considered in the context of HIV and could explain part of the variability in neurocognitive performance among individuals with HIV. SETTING: Women's Interagency HIV Study, a prospective, multisite, observational study of US women with and without HIV...
June 1, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29709973/short-term-efficacy-and-safety-of-adding-ezetimibe-to-currently-used-lipid-lowering-drugs-in-thai-hiv-infected-patients-receiving-protease-inhibitors
#3
Krisda Boonthos, Chankit Puttilerpong, Thitima Pengsuparp, Weerawat Manosuthi
Long-term complication of protease inhibitors (PIs) includes increased cardiovascular risks in HIV-infected patients due to dyslipidemia. Ezetimibe reduces LDL-C without drug interaction to PIs and statins. Furthermore, addition of ezetimibe on statins is an optional treatment in HIV-infected patients with uncontrolled dyslipidemia. The objective of this study was to determine short-term efficacy and safety of adding ezetimibe to currently used statins. Thirty-two patients received ezetimibe 10 mg daily added to their ongoing lipid-lowering therapy for 18 weeks...
April 27, 2018: Japanese Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29689541/management-of-long-term-complications-of-hiv-disease-focus-on-cardiovascular-disease
#4
Judith S Currier
HIV-infected individuals on effective antiretroviral therapy experience a number of non-AIDS noncommunicable diseases, such as cardiovascular disease, more frequently than uninfected individuals. Common pathways for such diseases are chronic immune activation and inflammation, including the prolonged inflammation associated with lower nadir CD4+ cell count. Prevention and treatment of non-AIDS conditions include treatment of traditional risk factors, lifestyle interventions, earlier initiation of antiretroviral therapy, and potentially therapies specifically targeting inflammation and immune activation (eg, statins)...
April 2018: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/29687016/dietary-patterns-and-physical-activity-correlate-with-total-cholesterol-independently-of-lipid-lowering-drugs-and-antiretroviral-therapy-in-aging-people-living-with-human-immunodeficiency-virus
#5
Alex Marzel, Roger D Kouyos, Sara Reinschmidt, Katharina Balzer, Fabienne Garon, Monica Spitaleri, Nicolas Matthes, Paolo Suter, Rainer Weber, Cornelia Staehelin, Thanh Doco Lecompte, Philip Tarr, Helen Kovari
Background: Hypercholesterolemia is a well established risk factor for coronary heart disease and is highly prevalent among human immunodeficiency virus (HIV)-positive persons. Antiretroviral therapy (ART) can both directly modify total cholesterol and have drug-drug interactions with statins. This makes investigating modifiable behavioral predictors of total cholesterol a pertinent task. Methods: To explore the association between diet and physical activity with cross-sectionally measured total cholesterol, we administered a validated Food-Frequency-Questionnaire to participants of the Swiss HIV Cohort Study ≥45 years old...
April 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29561173/evaluation-of-statin-eligibility-prescribing-practices-and-therapeutic-responses-using-atp-iii-acc-aha-and-nla-dyslipidemia-treatment-guidelines-in-a-large-urban-cohort-of-hiv-infected-outpatients
#6
Matthew E Levy, Alan E Greenberg, Manya Magnus, Naji Younes, Amanda Castel
Statin coverage has been examined among HIV-infected patients using Adult Treatment Panel III (ATP III) and American College of Cardiology/American Heart Association (ACC/AHA) guidelines, although not with newer National Lipid Association (NLA) guidelines. We investigated statin eligibility, prescribing practices, and therapeutic responses using these three guidelines. Sociodemographic, clinical, and laboratory data were collected between 2011 and 2016 for HIV-infected outpatients enrolled in the DC Cohort, a multi-center, prospective, observational study in Washington, DC...
February 2018: AIDS Patient Care and STDs
https://www.readbyqxmd.com/read/29424780/insulin-like-growth-factor-1-inversely-relates-to-monocyte-macrophage-activation-markers-in-hiv
#7
Lindsay T Fourman, Natalia Czerwonka, Sofia D Shaikh, Takara L Stanley, Tricia H Burdo, Kenneth C Williams, Kathleen V Fitch, Janet Lo, Steven K Grinspoon
OBJECTIVE: Monocyte/macrophage activation is increased among people with HIV, and may contribute to the heightened risk of atherosclerosis and neurocognitive dysfunction in this population. Insulin-like growth factor 1 (IGF-1) has been shown to attenuate the innate immune response in animal models of atherosclerosis and inflammatory bowel disease. We investigated, for the first time, relationships of circulating IGF-1 with monocyte/macrophage-specific indices among HIV-infected individuals and uninfected controls...
April 24, 2018: AIDS
https://www.readbyqxmd.com/read/29423787/human-immunodeficiency-virus-infection-antiretroviral-therapy-and-statin-a-clinical-update
#8
REVIEW
Hugo Ribeiro Zanetti, Leonardo Roever, Alexandre Gonçalves, Elmiro Santos Resende
PURPOSE OF REVIEW: This clinical update is intended to focus in relationship between HIV infection and use of antiretroviral therapy (ART) and statin. RECENT FINDINGS: Though ART significantly changed the course of HIV infection, it is related to numerous side effects principally to the lipid profile. In this way, statins became one of the most used lipid-lowering therapies in this population. In our clinical update, we evaluated studies that demonstrate the relationship and molecular mechanisms that HIV infection and ART use trigger dyslipidemia and also the use of statin to reduce this condition...
February 8, 2018: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/29419569/brief-report-statin-effects-on-myocardial-fibrosis-markers-in-people-living-with-hiv
#9
Christopher deFilippi, Robert Christenson, Jessica Joyce, Elli A Park, Ashley Wu, Kathleen V Fitch, Sara E Looby, Michael T Lu, Udo Hoffmann, Steven K Grinspoon, Janet Lo
BACKGROUND: In observational studies, patients with HIV have higher levels of soluble ST2 (sST2), galectin-3, and growth differentiation factor-15 (GDF-15) than non-HIV controls. As statins exert pleiotropic immunomodulatory effects that may affect markers of myocardial fibrosis, the objective of the current study is to determine whether biomarkers of myocardial fibrosis reflecting subclinical pathology may be modified by statin therapy in patients with HIV. SETTING AND METHODS: Forty HIV+ men and women participated in a single center 12-month randomized, double-blind placebo-controlled trial of atorvastatin 40 mg every day vs...
May 1, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29369166/novel-mediators-of-statin-effects-on-plaque-in-hiv-a-proteomics-approach
#10
Chris deFilippi, Janet Lo, Robert Christenson, Ida Grundberg, Lauren Stone, Markella V Zanni, Hang Lee, Steven K Grinspoon
OBJECTIVE: HIV patients have increased atherosclerotic coronary vascular disease (ASCVD), thought to be mediated through inflammatory mechanisms. We hypothesized that among asymptomatic HIV-infected patients with subclinical coronary plaque, statin therapy would modulate unique inflammatory and cardiovascular proteins in relation to change in subclinical coronary plaque volume. We tested this hypothesis using a novel proteomics approach. DESIGN: Forty HIV-infected participants were randomized to atorvastatin (40 mg/day) versus placebo, and underwent computed tomography coronary angiography to quantify plaque volume at baseline and 1 year...
April 24, 2018: AIDS
https://www.readbyqxmd.com/read/29228684/atorvastatin-downregulates-co-inhibitory-receptor-expression-by-targeting-ras-activated-mtor-signalling
#11
Isobel Okoye, Afshin Namdar, Lai Xu, Nicole Crux, Shokrollah Elahi
Regulation of T cell function in the steady state is mediated by co-inhibitory receptors or immune checkpoints such as PD-1, CTLA-4, TIM-3 and LAG-3. Persistent antigen stimulation, during chronic viral infections and cancer, results in sustained expression of multiple co-inhibitory receptors and subsequently poor effector T cell function. Immune checkpoint blockade using monoclonal antibodies against PD-1, PDL-1 and CTLA-4 has been implemented as an immunotherapy strategy- resulting in restoration of T cell function and reduction of viral load or tumour growth...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29138182/disparities-in-the-quality-of-cardiovascular-care-between-hiv-infected-versus-hiv-uninfected-adults-in-the-united-states-a-cross-sectional-study
#12
Joseph A Ladapo, Adam K Richards, Cassandra M DeWitt, Nina T Harawa, Steven Shoptaw, William E Cunningham, John N Mafi
BACKGROUND: Cardiovascular disease is emerging as a major cause of morbidity and mortality among patients with HIV. We compared use of national guideline-recommended cardiovascular care during office visits among HIV-infected versus HIV-uninfected adults. METHODS AND RESULTS: We analyzed data from a nationally representative sample of HIV-infected and HIV-uninfected patients aged 40 to 79 years in the National Ambulatory Medical Care Survey/National Hospital Ambulatory Medical Care Survey, 2006 to 2013...
November 14, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29067253/evidence-based-review-of-statin-use-in-patients-with-hiv-on-antiretroviral-therapy
#13
REVIEW
Daniel B Chastain, Kayla R Stover, Daniel M Riche
INTRODUCTION: As a result of improved safe and effective therapeutic options for human immunodeficiency virus (HIV), life expectancy of those living with HIV is increasing leading to new challenges (e.g., management of chronic diseases). Some chronic diseases (e.g., cardiovascular disease [CVD]), are up to two times more prevalent in patients with HIV. Statins are a mainstay of therapy for prevention of CVD; but, clinicians should be aware that not all statins are appropriate for use in the HIV population, especially those receiving antiretroviral therapy (ART)...
June 2017: Journal of Clinical & Translational Endocrinology
https://www.readbyqxmd.com/read/29058944/statin-drug-interactions-and-related-adverse-reactions-an-update
#14
REVIEW
Stefano Bellosta, Alberto Corsini
Statins reduce the risk of cardiovascular morbidity and mortality in patients with or at risk for cardiovascular disease and their use is expanding, especially in elderly. Statins are prescribed on a long-term basis and may undergo drug-drug interactions (DDIs) with other drugs. Statins have different safety and tolerability, and this might affect the possibility of DDIs with other cardiovascular drugs, increasing the risk of statin-associated myopathy and hepatotoxicity. Polypharmacy and pharmacogenetic variability are potential causes of statin DDIs...
January 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29058481/effects-of-antiretroviral-treatment-and-nadir-cd4-count-in-progression-to-cardiovascular-events-and-related-comorbidities-in-a-hiv-brazilian-cohort-a-multi-stage-approach
#15
Raquel de Vasconcellos Carvalhaes de Oliveira, Silvia Emiko Shimakura, Dayse Pereira Campos, Yara Hahr Marques Hökerberg, Flaviana Pavan Victoriano, Sayonara Ribeiro, Valdiléa G Veloso, Beatriz Grinsztejn, Marilia Sá Carvalho
The use of highly active antiretroviral therapy has resulted in changes of comorbidity profile in people living with HIV (PLHIV), increasing non-AIDS-related events. The occurrence of cardiovascular events is greater in PLHIV, but the mechanism responsible for it is still controversial. This article aimed to investigate factors associated with the progression to cardiovascular events in PLHIV using HAART. A 15-years cohort study with 1135 PLHIV was conducted in Rio de Janeiro-Brazil. Clinical progression was stratified in five states: No comorbidities (s1), arterial hypertension (s2), lipid abnormalities (s3), hypertension and lipid abnormalities (s4) and major cardiovascular events (stroke, coronary artery disease, thrombosis or death) (s5)...
October 23, 2017: AIDS Care
https://www.readbyqxmd.com/read/29038899/the-use-of-primary-prevention-statin-therapy-in-those-predisposed-to-atherosclerosis
#16
REVIEW
Michael Garshick, James A Underberg
PURPOSE OF REVIEW: Many guidelines exist for the use of statins in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Few have focused on disease specific states that predispose to ASCVD. This review is intended to focus on the recommendations and evidence in inflammatory diseases that predispose to an increased risk of ASCVD beyond what conventional cardiac risk scores would predict. RECENT FINDINGS: Certain autoimmune inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematous (SLE), and psoriasis/psoriatic arthritis have all been shown to increase the risk of ASCVD...
October 17, 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/29020215/long-term-use-of-proton-pump-inhibitors-is-associated-with-increased-microbial-product-translocation-innate-immune-activation-and-reduced-immunologic-recovery-in-patients-with-chronic-human-immunodeficiency-virus-1-infection
#17
J A Serpa, A M Rueda, A Somasunderam, N S Utay, D Lewis, J P Couturier, K G Breaux, M Rodriguez-Barradas
Background: Translocation of microbial products from the damaged gut causes increased immune activation in human immunodeficiency virus (HIV). Proton pump inhibitors (PPIs) predispose to bacterial overgrowth in the gut. We hypothesized that long-term use of PPIs is associated with greater microbial translocation and immune activation in HIV. Methods: HIV-infected persons on suppressive antiretroviral therapy (ART), including those receiving long-term PPIs (PPI+ group) or not (PPI- group), were enrolled...
October 30, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29020184/risk-of-acute-liver-injury-after-statin-initiation-by-human-immunodeficiency-virus-and-chronic-hepatitis-c-virus-infection-status
#18
Dana D Byrne, Janet P Tate, Kimberly A Forde, Joseph K Lim, Matthew Bidwell Goetz, David Rimland, Maria C Rodriguez-Barradas, Adeel A Butt, Cynthia L Gibert, Sheldon T Brown, Roger Bedimo, Matthew S Freiberg, Amy C Justice, Jay R Kostman, Jason A Roy, Vincent Lo Re
Background: Patients with human immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescribed statins as treatment for metabolic/cardiovascular disease, but it remains unclear if the risk of acute liver injury (ALI) is increased for statin initiators compared to nonusers in groups classified by HIV/HCV status. Methods: We conducted a cohort study to compare rates of ALI in statin initiators vs nonusers among 7686 HIV/HCV-coinfected, 8155 HCV-monoinfected, 17739 HIV-monoinfected, and 36604 uninfected persons in the Veterans Aging Cohort Study (2000-2012)...
October 16, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29020174/the-impact-of-statin-and-angiotensin-converting-enzyme-inhibitor-angiotensin-receptor-blocker-therapy-on-cognitive-function-in-adults-with-human-immunodeficiency-virus-infection
#19
Kristine M Erlandson, Douglas Kitch, C William Wester, Robert C Kalayjian, Edgar Turner Overton, Jose Castillo-Mancilla, Susan L Koletar, Constance A Benson, Thomas B Campbell, Kevin Robertson, Judith J Lok
Background: Although statins, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are generally well tolerated, the impact of these therapies individually or in combination on the change in neurocognitive function in persons with human immunodeficiency virus infection is unknown. Methods: The study included participants in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort participants not receiving a statin or ACEI/ARB within 30 days of first neurologic assessment (baseline), with assessments by NPZ-3 (z score of averaged Trailmaking A and B tests and digit symbol test [DST]) from ≥2 measurements...
November 29, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28994502/pro-protein-subtilisin-kexin-9-pcsk9-inhibition-in-practice-lipid-clinic-experience-in-2-contrasting-uk-centres
#20
Monika Kohli, Kinjal Patel, Zofia MacMahon, Radha Ramachandran, Martin A Crook, Timothy M Reynolds, Anthony S Wierzbicki
BACKGROUND: Prescribing criteria have been suggested for proprotein convertase subtilisin kexin-9 (PCSK-9) inhibitors but few studies exist of their real-world effectiveness. METHODS: This study audited PCSK-9 inhibitor therapy in 105 consecutive patients from two hospital centres-a university hospital (UH; n = 70) and a district general hospital (DGH; n = 35). Baseline characteristics including cardiovascular disease risk factors, NICE qualification criteria, efficacy and side effects were assessed...
November 2017: International Journal of Clinical Practice
keyword
keyword
14751
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"